Project Grant R03AG084948
Award Date
8/15/24
Completion Date
5/31/26
Dollars Obligated
$789K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This three-year Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund $2,136,033 in research under the Aging Research program (CFDA 93.866). The grant recipient, Case Western Reserve University in partnership with University Hospitals of Cleveland, will investigate the role of the CHCHD6 protein in Alzheimer's disease pathology and potential therapeutic interventions. Specifically, the researchers will study the causes and consequences...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $575,667 to the University of Mississippi Medical Center to conduct research on the role of activated protein C (APC) signaling in the pathogenesis of Alzheimer's disease (AD). The project aims to characterize how APC signaling impacts the metabolic and inflammatory processes underlying AD, as well as evaluate the potential of APC derivatives to improve neurological function in AD. A...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $644,000.00 to Case Western Reserve University to investigate the role of the METTL3-mediated m6A RNA modification pathway in amyloid-beta (Aβ) metabolism and its contribution to Alzheimer's disease pathology. The researchers aim to determine how METTL3 deficiency and reduced m6A methylation modulate the expression and metabolism of genes involved in Aβ production and degradation, with the...
The federal Project Grant award R01AG082382, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), is funding research to investigate the role of oxidative stress and microglial dysfunction in Alzheimer's disease. The $2,270,708 grant, awarded on August 15, 2024, will be utilized by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a 5-year research project aimed at discovering new molecular mechanisms...
This $200,323 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research by the University of South Florida to investigate the aggregation of amyloid-beta (Aβ) peptides during metabolic stress and spreading depolarization events in the brain. The project will utilize multiscale modeling, high-resolution microscopy, antibody staining, and paralysis phenotype testing in C. elegans to determine how physiochemical changes...
This $528,876 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will enable Emory University to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). The key products and services to be delivered include: Developing new analytical tools to integrate transcriptome-wide association studies (TWAS) and proteome-wide association studies...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant under CFDA 93.866 (Aging Research) to The Leland Stanford Junior University to develop a toolkit called "Combo-Seq/Tag" for studying the genetic interactions underlying Alzheimer's disease (AD) pathogenesis. The project aims to combine precisely installed AD risk alleles (Combo-Seq) with a multiplex protein tagging tool (Combo-Tag) to enable efficient perturbation of AD risk genes and multi-omics readouts in human...
The National Institute on Aging (NIA) awarded a $2,335,492 Project Grant under the Aging Research federal grant program (CFDA 93.866) to Battelle Memorial Institute's Pacific Northwest National Laboratory Division to conduct research on the role of brain lipoproteins in Alzheimer's disease. The key objectives are to: 1) Assess the impact of different apolipoprotein E (ApoE) isoforms on the distribution, composition, and amyloid-beta binding ability of brain lipoproteins, and 2) Determine the...